 Y-mAbs Therapeutics Inc NASDAQ: YMAB recently concluded a Type B meeting with the FDA regarding omburtamab in CNSleptomeningeal metastasis from neuroblastoma. The company received requests from the agency for additional data concerning the granularity of data from identified historical control groups. 